{"entity":{"id":"nct05211570","kind":"trial","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by AB Science, now recruiting.","summary":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT05211570 by AB Science, with 78 participants planned, started 2022-06-01 and due to reach its primary completion in 2026-08. Interventions recorded: AB8939 and Venetoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05211570","url":"https://clinicaltrials.gov/study/NCT05211570"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax"],"companies":["ab-science"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05211570","phase":"1/2","setting":"A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"AB Science","enrolled":78,"outcomes":[]},"route":"/trials/nct05211570/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/"}]}}